Price and Volume Buzzers for February 16: Natco Pharma, JB Chemical, and Torrent Chemical Jump Up to 12%; Here’s Why


By Dalal Street Investment Journal (DSIJ)

Summary:


Natco Pharma, Torrent Pharmaceuticals, and JB Chemicals & Pharmaceuticals were among the top gainers in the NIFTY 500 on February 16. The rally was driven by strong Q3FY26 earnings, regulatory approval for a key product launch, and strategic acquisition-led optimism, even as broader market sentiment remained subdued.

Price and Volume Buzzers for February 16:

Here’s Why Natco Pharma Share Price Jumped 12%

Natco Pharma is trading up about 12%, post-robust Q3FY26 results. On February 16, the Natco Pharma share price surged with robust volume activity. Volume jumped over 11x to 69.3 lakh shares on the NSE as compared to the 30-day average of 5.9 lakh shares. 

This surge came after Natco received CDSCO approval to manufacture and market a generic semaglutide injection in India. Following approval, the company will launch the product commercially in March 2026. Semaglutide, often called the miracle drug, is used for weight loss as well as type 2 diabetes.

This development followed its Q3FY26 earnings announcement. In Q3FY26, total revenue increased by 8.3% year-on-year to ₹705.4 crore, while EBITDA was flat at ₹216.8 crore, in comparison to ₹215.1 crore in the same period last quarter. Margin declined by 230 bps to 30.7%. Still, consolidated net profit jumped 14.3% to ₹151.3 crore.

Torrent Pharmaceuticals Surged Over 5%, Key Triggers 

With a 5.4% gain, Torrent Pharmaceuticals is another stock leading the list of gainers. This surge also followed a 3x jump in trading volume to 9.21 lakh, compared with the 30-day average of 2.77 lakh.

Torrent reported robust numbers that met street estimates. Revenue rose by 18% year-on-year to ₹3,303 crore in Q3FY26. Operating EBITDA increased 19% to ₹1,088 crore, with margins at 33%. Net profit increased by 26% to ₹635 crore. In addition to strong performance, Torrent completed the acquisition of a controlling stake in JB Chemicals. In addition to this, Torrent Pharmaceuticals announced an interim dividend of ₹29 per equity share. 

JB Chemicals & Pharmaceuticals Merger with Torrent Pharmaceuticals 

JB Chemicals & Pharmaceuticals is another stock leading the list of gainers in the NIFTY 500 basket, up 5.44%. This surge followed a 3x jump in trading volume to 6.89 lakh, compared with the 30-day average of 1.98 lakh. This surge followed the company’s successful acquisition by Torrent Pharma. The merger with Torrent Pharmaceuticals is expected to be completed within 6-9 months.

JB Chemicals also reported robust numbers in Q3FY26. Revenue increased by 11% to ₹1065 crore, while EBITDA surged 16% to ₹296 crore. Margins expanded by 140 basis points to 27.8%, leading to a 22% increase in net profit to ₹198 crore.

Conclusion 

Natco Pharma, Torrent Pharmaceuticals, and JB Chemicals stood out in an otherwise range-bound market, driven by stock-specific triggers. Natco surged on CDSCO approval for generic semaglutide. Torrent gained after a steady quarterly performance and the acquisition of its controlling stake in JB Chemicals. Meanwhile, JB Chemicals moved higher on merger-related optimism, supported by a sharp spike in trading volumes across all three stocks.

About the Author

SEBI Registered Research Analyst (INH000006396).


Founded in 1986, Dalal Street Investment Journal (DSIJ) brings decades of experience in India’s equity markets. DSIJ's research combines fundamental analysis with price action, guided by disciplined risk management and capital preservation. They follow a structured, data-driven approach designed to help investors and traders make informed decisions beyond short-term market noise. 

Published Date : 16 Feb 2026

Disclaimer :

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.


Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited



This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing. 

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

11 lakh+ Users

icon-with-text

4.8 App Rating

icon-with-text

4 Languages

icon-with-text

₹7,900+ Cr MTF Book

icon-with-text